Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai's Nuance Pharma in a $225 million deal.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback